The FDA declined to approve Summit Therapeutics' ivonescimab for lung cancer because the pivotal study did not demonstrate a statistically significant overall survival benefit. The investigational PD-1/VEGF bispecific antibody, combined with chemotherapy, reduced the risk of disease progression or death by 48% relative to chemotherapy alone, but the agency considered the survival evidence insufficient to establish a favorable benefit-risk profile. Summit submitted updated analyses suggesting consistent effects across Asian and Western populations, although the agency's decision relied on the primary trial analysis. The drug was licensed from China's Akeso under a deal worth up to $5 billion, and Summit expects results from another late-stage lung cancer study before year-end.
Reuters
Why it matters strategically
This is a significant test of oncology development strategy and the evidentiary requirements for regulatory approval.
Progression-free survival (PFS) can be clinically meaningful, but a substantial PFS improvement does not necessarily establish improved overall survival (OS), particularly when treatment toxicity, subsequent therapies, and patient heterogeneity affect the final benefit-risk assessment.
The decision also has implications for cross-border licensing of oncology assets developed initially in China.